Evidence map›Paper›PMID 39099656›Full record

ArticlePeerJ2024

Immune infiltration and prognosis in gastric cancer: role of NAD+ metabolism-related markers.

Yu Xing, Zili Zhang, Wenqing Gao, Weiliang Song, Tong Li

Abstract read
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu XingThe Third Central Clinical College of Tianjin Medical University, Tianjin, China.
Zili ZhangThe Third Central Clinical College of Tianjin Medical University, Tianjin, China.
Wenqing GaoThe Third Central Hospital of Tianjin, Tianjin, China.
Weiliang SongThe Third Central Hospital of Tianjin, Tianjin, China.
Tong LiThe Third Central Clinical College of Tianjin Medical University, Tianjin, China.

Funding

Tianjin Key Medical Discipline (Specialty) Construction ProjectTianjin Science and Technology Project
6 · The paper itself

Abstract

Background: This study endeavored to develop a nicotinamide adenine dinucleotide (NAD+) metabolism-related biomarkers in gastric cancer (GC), which could provide a theoretical foundation for prognosis and therapy of GC patients. Methods: In this study, differentially expressed genes (DEGs1) between GC and paraneoplastic tissues were overlapped with NAD+ metabolism-related genes (NMRGs) to identify differentially expressed NMRGs (DE-NMRGs). Then, GC patients were divided into high and low score groups by gene set variation analysis (GSVA) algorithm for differential expression analysis to obtain DEGs2, which was overlapped with DEGs1 for identification of intersection genes. These genes were further analyzed using univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses to obtain prognostic genes for constructing a risk model. Enrichment and immune infiltration analyses further investigated investigate the different risk groups, and qRT-PCR validated the prognostic genes. Results: Initially, we identified DE-NMRGs involved in NAD biosynthesis, with seven ( Conclusion: In this study, seven NAD+ metabolism-related markers were established, which is of great significance for the development of prognostic molecular biomarkers and clinical prognosis prediction for gastric cancer patients.

Indexed as

Biomarkers, TumorNADStomach NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorNADGastric cancerNicotinamide adenine dinucleotide (NAD+) metabolismPrognosisRisk signature

Identifiers

PMID39099656
PMCPMC11297443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.